CONCLUSIONS METHODS
 A hybrid epidemiological and claims-based approach was used to forecast the proportion of patients with testosterone deficiency (TD) in Ontario. (Table 1)  The BIA included costs of TRTs and the key cost drivers of physician visits, administering injectable TRTs, testosterone level testing and EAP evaluation and processing. TRT drug costs consisted of average yearly expenditures claimed (IMS Health data).
 JSS Medical Research evaluated the ODPRN scenarios with and without inappropriate TRT use over a 3-year period. Option A assumed the statusquo where no change was applied to the current coverage criteria while option B restricted all forms of TRT to the EAP, option C restricted oral and topical forms of TRT only, and option D restricted topical forms of TRT only.
 Due to unsubstantiated evidence of inappropriate use, the base case analysis relied on expert opinion, and assumed all users of TRT would qualify. The sensitivity analyses replicated the ODPRN assumptions of inappropriate use, terminating coverage of 46%, 15% and 7% of patients in options B, C and D, respectively.  The ODPRN conducted a BIA from the narrow perspective of prescription drug costs only, driven by the presumption that all formulations of TRT are of equal therapeutic value.
 JSS Medical Research replicated the BIA from the perspective of the Ministry of Health including the cost of administering injectable TRTs, laboratory testing, physician visits and EAP evaluation and processing.
 Important differences between the ODPRN and JSS Medical Research estimates with respect to budgetary forecasts (up to 6.2M) were observed.
 The ODPRN assumed that a high proportion of TRT use was inappropriate, however this was not based on patient chart review or formal assessment. The presence of a claim for testosterone level testing and/or utilization rates from other provinces were used as a proxy for ''appropriate'' use. This method was limited as patients who used testosterone tests not publicly reimbursed, who claimed the tests on a private insurance or paid out-ofpocket would therefore be assumed to inappropriately use TRT.
 Another important difference can be attributed to the ODPRN assumption of exponential (or power) growth, which was not supported by more recent public drug plans claims. (Figure 1)  Although less costly from a drug acquisition standpoint, injectable TRT is associated with high physician burden due to arduous administration. Selfadministration, consisting of deep intra-muscular injections of a highly viscous solution and requiring physical force, does not offer a clinically relevant alternative to physician administration. 
OBJECTIVES:
The Ontario Drug Policy Research Network (ODPRN) published recommendations to restrict reimbursement and coverage criteria of testosterone replacement therapy (TRT) in Ontario to the Exceptional Access Program (EAP). The ODPRN's budget impact analysis (BIA) evaluated the following 4 reimbursement scenarios: no reimbursement change (option A), restricting coverage of all forms of TRT to the EAP (option B), restricting oral and topical forms only (option C), or restricting topical forms only (option D). The analysis assumed exponential growth of TRT expenditures and inappropriate use in 7%-46% of patients and took into consideration drug prescription costs alone, resulting in forecasted savings ranging from $7-$16 million over a 3-year period. JSS Medical Research performed the BIA from the ministry of health perspective. METHODS: Our hybrid epidemiological and claims-based BIA considered both the costs of TRT and key cost drivers associated with reimbursement policy change: physician visits, injectable TRT administration fees, testosterone level testing, and EAP evaluation and processing. Ontario prescription drug expenditures based on claims data, as well as published literature and expert opinion were utilized. We evaluated the impact of the ODPRN scenarios with and without inappropriate TRT use over a 3-year period.
RESULTS: Based on the JSS assumption that all patients currently qualify for TRT, and taking into consideration key cost drivers, option B would cost $1.01 million; option C $766,000, and option D $252,000. A sensitivity analysis was undertaken using ODPRN assumptions of inappropriate use, in which JSS Medical Research forecasted savings of $373,000-$13.4 million as opposed to savings of $7-$16 million forecasted by the ODPRN.
CONCLUSIONS: ODPRN savings exclude key cost drivers and assume a greater magnitude of inappropriate use. The burden of the policy change could completely offset savings and generate costs of up to $1 million to the healthcare budget. Healthcare policy recommendations based on drug costs alone underestimate the true cost to the Ministry of Health, shifting, and in this case creating additional costs to other areas of the healthcare system.
OBJECTIVES
A) To perform a BIA encompassing all costs to the Ministry of Health that are associated with coverage inclusion criteria change, for each reimbursement option. B) Guide decision-makers on the proposed changes to the TRT reimbursement policy, and its impact on the healthcare system. Please note that the drug cost included the costs of injectable TRT administration.
Criteria

RESULTS
 Option B restricted all forms of TRT to EAP reimbursement. Expenditures to the Ministry of Health were forecasted at $10.9 million, $10.2 million and $10.5 million in 2016, 2017 and 2018, respectively.
 When compared to the current forecast (option A - Table 2 ), option B results in incremental costs to the Ministry of Health of $1.01 million over 3 years. (Table  3 ) We thank BGP Pharma ULC, doing business as Mylan EPD ("Mylan EPD") for providing the funds necessary for the analysis. JSS Medical Research had full control of the methodology and writing of the report. JSS Medical Research is grateful for the partnership with IMS Health Inc., provider of the claims data utilized in the analysis.
 When compared to the current forecast (option A - Table 2 ), option C results in incremental costs to the Ministry of Health of $766,000 over 3 years. (Table 4 ) Please note that the drug cost included the costs of injectable TRT administration.
 Option A represented the status-quo and evaluated the costs of no change to current coverage criteria. Expenditures to the Ministry of Health were forecasted at $9.9 million, $10.2 million and $10.5 million in 2016, 2017 and 2018, respectively. 
